Orion Biotech Opportunities Corp. Units
ORIAU
ORIAU was delisted on the 25th of April, 2023.
11 hedge funds and large institutions have $25.1M invested in Orion Biotech Opportunities Corp. Units in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less funds holding
Funds holding: 14 → 11 (-3)
24% less capital invested
Capital invested by funds: $33.2M → $25.1M (-$8.02M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$1.71M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$825K |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$488K |
| 4 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
-$24.5K |
| 5 |
WC
Wealthspring Capital
West Harrison,
New York
|
-$19.6K |
ORIAU Hedge Fund Activity: Q2 2022 in Review
11 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Units (ORIAU) for Q2 2022, worth a combined $25.1M — down 24% from $33.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ORIAU and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 0 added.
The largest seller was First Trust Capital Management, exiting entirely with an estimated $1.71M sold.
- 11 institutional investors held Orion Biotech Opportunities Corp. Units (ORIAU) as of Q2 2022, down from 14 in Q1 2022.
- Funds reported $25.1M of Orion Biotech Opportunities Corp. Units stock for Q2 2022, down 24% quarter-over-quarter.
- 0 funds opened new Orion Biotech Opportunities Corp. Units positions in Q2 2022 and 3 closed out, a net change of -3 holders.
- The largest Orion Biotech Opportunities Corp. Units seller in Q2 2022 was First Trust Capital Management, an estimated $1.71M sold.
Based on aggregated 13F filings for Q2 2022.